Díaz-Infante Ernesto, Sitges Marta, Vidal Bàrbara, Mont Luis, Delgado Victoria, Marigliano Alba, Macias Alfonso, Tolosana Jose María, Tamborero David, Azqueta Manel, Roig Eulàlia, Paré Carles, Brugada Josep
Department of Cardiology, Thorax Institute, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.
Am J Cardiol. 2007 Jul 1;100(1):84-9. doi: 10.1016/j.amjcard.2007.02.054. Epub 2007 May 15.
There are discordant data about the utility of septal-to-posterior wall motion delay (SPWMD) assessed using M-mode echocardiography to predict an improvement with cardiac resynchronization therapy (CRT). Baseline SPWMD was measured using M-mode in a parasternal short-axis view in a series of 67 patients undergoing CRT and followed up after 6 months. Heart failure was caused by coronary artery disease in 27 patients. Clinical responders were patients who were alive, had not undergone heart transplantation, and also increased the distance walked in 6 minutes by >10%. Baseline SPWMDs were mean 155 +/- 113 ms and median 135. Thirty-four patients (51%) had an SPWMD >130 ms. At 6-month follow-up, there were 17 nonresponders. At baseline, there were no significant differences between patients with SPWMD >130 or <130 ms in age, drug therapy, permanent atrial fibrillation, New York Heart Association functional class, underlying cause of cardiomyopathy, QRS duration, left ventricular (LV) ejection fraction, LV dimensions, or neurohormonal activation (norepinephrine and atrial and brain natriuretic peptide). At 6-month follow-up, baseline SPWMD was not associated with clinical response, New York Heart Association functional class, distance walked in 6 minutes, LV reverse remodeling, or neurohormonal activation. SPWMD >130 ms was also not a predictor. In conclusion, SPWMD is not a good predictor of response to CRT.
关于使用M型超声心动图评估室间隔至后壁运动延迟(SPWMD)以预测心脏再同步治疗(CRT)疗效的数据并不一致。在一系列67例接受CRT治疗的患者中,采用M型超声心动图在胸骨旁短轴视图中测量基线SPWMD,并在6个月后进行随访。27例患者的心力衰竭由冠状动脉疾病引起。临床反应者是指存活、未接受心脏移植且6分钟步行距离增加>10%的患者。基线SPWMD的平均值为155±113毫秒,中位数为135毫秒。34例患者(51%)的SPWMD>130毫秒。在6个月的随访中,有17例无反应者。在基线时,SPWMD>130毫秒或<130毫秒的患者在年龄、药物治疗、永久性心房颤动、纽约心脏协会功能分级、心肌病的潜在病因、QRS时限、左心室(LV)射血分数、LV尺寸或神经激素激活(去甲肾上腺素以及心房和脑钠肽)方面无显著差异。在6个月的随访中,基线SPWMD与临床反应、纽约心脏协会功能分级、6分钟步行距离、LV逆向重构或神经激素激活无关。SPWMD>130毫秒也不是一个预测指标。总之,SPWMD不是CRT反应的良好预测指标。